Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Aclaris opens mid-stage lichen planus study for oral ITK/JAK3 drug modzatinib

The 100-patient placebo-controlled trial will read out its first cohort, in oral erosive disease, in the second half of 2027, leaving the commercial case unproven for now.

16 Nov 2026 · Aclaris Therapeutics, Inc. ACRS · Company news

Aclaris Therapeutics has dosed off a new stage in the development of modzatinib, also known as ATI-2138, by launching a Phase 2b study in patients with moderate-to-severe lichen planus. The company announced the move on 16 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Aclaris Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →